A Russian S-400 air defense missile system in Moscow's Red Square. Photo: Vasily Maximov / AFP via Getty Images

India may close a major defense deal with Russia as early as next week, when Indian Defense Minister Nirmala Sitharaman will make her first trip to Moscow. The deal covers two S-400 air defense systems, which include radar, missile launchers and command center technology.

Why it matters: In August 2017, President Trump signed into law the Countering America’s Adversaries through Sanctions Act (CAATSA) against Russia. Because the sanctions target any country trading with Russia's defense and intelligence sectors, India's pending deal may put it on a collision course with the U.S.

The background: Approximately 60% of India’s defense inventory is Russian-made, a legacy of India’s Cold War–era relationship with the Soviet Union. While the U.S. has become its second largest defense supplier — mainly of aircraft and artillery — India still relies heavily on Russian equipment, such as submarines and missiles, that the U.S. has been unwilling to provide.

India has good reason to want high-end weapons systems: It is the only country in the world that has contested borders with two nuclear neighbors — Pakistan and China — and has fought wars with both. Forcing India to abruptly cut off Russian supplies would create unacceptable risk to India's self-defense. If forced to choose between a robust, well-equipped military and U.S. goodwill, India would likely choose the former.

What's next: These sanctions, like penalties the U.S. imposed after India's nuclear tests in the 1990s, would sour relations. At worst, they could stoke domestic backlash and close off U.S. defense sales to India for the foreseeable future. Given bipartisan support for the U.S.–India defense relationship, Congress should grant India waiver authority under CAATSA. Without waivers, other important regional partners, like Vietnam and Indonesia, are also likely to trigger sanctions.

The bottom line: India warrants an exemption from these secondary sanctions, as does any country with which the U.S. is forging new and strategically important defense relations.

Cara Abercrombie is a visiting scholar in the South Asia Program at the Carnegie Endowment for International Peace.

Go deeper

Updated 4 mins ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Global: Total confirmed cases as of 9 p.m. ET: 13,273,537 — Total deaths: 577,006 — Total recoveries — 7,367,106Map.
  2. U.S.: Total confirmed cases as of 9 p.m. ET: 3,424,304 — Total deaths: 136,432 — Total recoveries: 1,049,098 — Total tested: 41,764,557Map.
  3. Politics: Biden welcomes Trump wearing mask in public but warns "it’s not enough"
  4. Public health: Four former CDC heads say Trump's undermining of agency puts lives at risk — CDC director: U.S. could get coronavirus "under control" in 4–8 weeks if all wear masks.

Bank CEOs brace for worsening economic scenario

JPMorgan CEO Jamie Dimon. Photo: J. Lawler Duggan/For The Washington Post via Getty Images

Wells Fargo swung to its first loss since the financial crisis — while JPMorgan Chase and Citigroup reported significantly lower profits from a year earlier — as the banks set aside billions of dollars more in the second quarter for loans that may go bad.

Why it matters: The cumulative $28 billion in loan loss provisions that banks have so far announced they’re reserving serves as a signal they’re preparing for a colossal wave of loan defaults as the economy slogs through a coronavirus-driven downturn.

3 hours ago - Health

Moderna's vaccine spurred immune system response to coronavirus

Moderna's stock rose 16% after hours on this news. Photo: Jakub Porzycki/NurPhoto via Getty Images

Healthy volunteers who took Moderna's coronavirus vaccine candidate appeared to generate an immune system response to the virus, and there were "no trial-limiting safety concerns," according to a new study published in the New England Journal of Medicine.

Why it matters: The phase one trial is still small and does not definitively determine how effective the vaccine is. But Anthony Fauci of the National Institutes of Health, which is running the trial, told the Wall Street Journal that these data make it "pretty clear that this vaccine is capable of inducing quite good [levels] of neutralizing antibodies."